NCT04510012View on ClinicalTrials.gov

Characterizing the Immune Response and Neuronal Damage in COVID-19

CompletedOBSERVATIONAL
Enrollment

88

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

December 18, 2020

Study Completion Date

January 30, 2021

Conditions
SARS-CoV InfectionCovid-19
Interventions
OTHER

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.

Trial Locations (1)

3010

Bern University Hospital, Bern

All Listed Sponsors
collaborator

University of Bern

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04510012 - Characterizing the Immune Response and Neuronal Damage in COVID-19 | Biotech Hunter | Biotech Hunter